Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis

Next Previous
Trial Profile

A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Therapeutic Use
  • Sponsors Intercept Pharmaceuticals

Most Recent Events

  • 24 Oct 2018 Results of retrospective analysis evaluating the effect of Obeticholic acid on bilirubin from Poise, 201, and 202, presented at the 26th United European Gastroenterology Week.
  • 14 Apr 2018 Results of a retrospective analysis assessing the effect of obeticholic acid on bilirubin in patients with high baseline bilirubin from a phase 3 trial (POISE and its open label extension) and two 3-month phase 2 PBO-controlled trials (201, 202 and their open label extensions), presented at The International Liver Congress 2018.
  • 10 Oct 2017 Primary endpoint has been met. (Alkaline Phosphatase (AP) Levels), according to results published in the Hepatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top